Restoring cancer's death sentence

被引：18

作者：

Letai, Anthony ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

来源：

CANCER CELL | 2006年 / 10卷 / 05期

关键词：

D O I：

10.1016/j.ccr.2006.10.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this issue of Cancer Cell, two groups present data on the function of an antagonist of BCL-2, ABT-737. Both groups find that expression of MCL-1, an antiapoptotic protein related to BCL-2, is a key determinant of resistance to ABT-737. Lowering MCL-1 levels is an effective adjunct to BCL-2 antagonism, and both groups suggest ways that this might be accomplished practically in a clinical setting. The mechanism by which ABT-737 selectively kills cancer cells is discussed below in the context of these and prior reports of ABT-737's function. Antagonism of BCL-2 is an exciting anticancer strategy that may soon become a clinical reality.

引用

页码：343 / 345

页数：3

共 8 条

[1] Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members [J].

Certo, Michael ;

Moore, Victoria Del Gaizo ;

Nishino, Mari ;

Wei, Guo ;

Korsmeyer, Stanley ;

Armstrong, Scott A. ;

Letai, Anthony .

CANCER CELL, 2006, 9 (05) :351-365

[2] Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function [J].

Chen, L ;

Willis, SN ;

Wei, A ;

Smith, BJ ;

Fletcher, JI ;

Hinds, MG ;

Colman, PM ;

Day, CL ;

Adams, JM ;

Huang, DCS .

MOLECULAR CELL, 2005, 17 (03) :393-403

[3] BH3 domains of BH3-only proteins differentially regulate bax-mediated mitochondrial membrane permeabilization both directly and indirectly [J].

Kuwana, T ;

Bouchier-Hayes, L ;

Chipuk, JE ;

Bonzon, C ;

Sullivan, BA ;

Green, DR ;

Newmeyer, DD .

MOLECULAR CELL, 2005, 17 (04) :525-535

[4] Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics [J].

Letai, A ;

Bassik, MC ;

Walensky, LD ;

Sorcinelli, MD ;

Weiler, S ;

Korsmeyer, SJ .

CANCER CELL, 2002, 2 (03) :183-192

[5] A membrane-targeted BID BCL-2 homology 3 peptide is sufficient for high potency activation of BAX in vitro [J].

Oh, Kyoung Joon ;

Barbuto, Scott ;

Pitter, Kenneth ;

Morash, Joel ;

Walensky, Loren D. ;

Korsmeyer, Stanley J. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (48) :36999-37008

[6] An inhibitor of Bcl-2 family proteins induces regression of solid tumours [J].

Oltersdorf, T ;

Elmore, SW ;

Shoemaker, AR ;

Armstrong, RC ;

Augeri, DJ ;

Belli, BA ;

Bruncko, M ;

Deckwerth, TL ;

Dinges, J ;

Hajduk, PJ ;

Joseph, MK ;

Kitada, S ;

Korsmeyer, SJ ;

Kunzer, AR ;

Letai, A ;

Li, C ;

Mitten, MJ ;

Nettesheim, DG ;

Ng, S ;

Nimmer, PM ;

O'Connor, JM ;

Oleksijew, A ;

Petros, AM ;

Reed, JC ;

Shen, W ;

Tahir, SK ;

Thompson, CB ;

Tomaselli, KJ ;

Wang, BL ;

Wendt, MD ;

Zhang, HC ;

Fesik, SW ;

Rosenberg, SH .

NATURE, 2005, 435 (7042) :677-681

[7] A stapled BID BH3 helix directly binds and activates BAX [J].

Walensky, Loren D. ;

Pitter, Kenneth ;

Morash, Joel ;

Oh, Kyoung Joon ;

Barbuto, Scott ;

Fisher, Jill ;

Smith, Eric ;

Verdine, Gregory L. ;

Korsmeyer, Stanley J. .

MOLECULAR CELL, 2006, 24 (02) :199-210

[8] Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins [J].

Willis, SN ;

Chen, L ;

Dewson, G ;

Wei, A ;

Naik, E ;

Fletcher, JI ;

Adams, JM ;

Huang, DCS .

GENES & DEVELOPMENT, 2005, 19 (11) :1294-1305

← 1 →